Xiaomeng Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaomeng Yang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Yongjun Wang
Department of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China
8 shared publications Xia Meng
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
6 shared publicationsHao Li
China National Clinical Research Center for Neurological Diseases Beijing China
5 shared publications- Zixiao Li
Department of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China
5 shared publications - Xingquan Zhao
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University
4 shared publications Yong Jiang
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
4 shared publications
Latest Publications
- 28 May 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (7) , e70320
A Mixed Single‐Echo and Multiecho MyoFoldstar for Simultaneous Quantification of Myocardial T 1 , T 2 , T 2 *, and Wall Motion
This study aimed to propose a mixed single‐echo and multiecho MyoFoldstar sequence enabling simultaneous myocardial multiparametric mapping and wall‐motion quantification. MyoFoldstar is designed as a 2D, single breath‐holding sequence that sequentially performs joint T 1 / T 2 mapping, T 2 * mapping, and cine imaging within 17 heartbeats, using a golden‐angle radial gradient‐echo (GRE) readout and ECG synchronization. The joint T 1 / T 2 mapping collects seven single‐shot, single‐echo images on the first seven heartbeats with inversion and T 2 preparation ( T 2 prep). The subsequent T 2 * mapping acquires multishot, multiecho data over six heartbeats, followed by segmented cine with a single‐echo readout over four heartbeats. In vivo feasibility was demonstrated in 12 healthy volunteers at 3 T and compared with conventional single‐task sequences (MOLLI and SASHA for T 1 , T 2 prep bSSFP for T 2 , and BB‐meGRE for T 2 *). Accuracy was validated in phantom studies. Both in vivo and phantom studies demonstrated the feasibility of MyoFoldstar for simultaneously acquiring cardiac T 1 , T 2 , T 2 *, and cine imaging. MyoFoldstar‐derived myocardial T 1 (1521 ± 102 ms), T 2 (43.2 ± 3.0 ms), and T 2 * (19.2 ± 2.4 ms) showed good agreement with values from conventional single‐task sequences ( T 1 : 1248 ± 35 ms by MOLLI and 1580 ± 38 ms by SASHA; T 2 : 43.5 ± 2.2 ms by T 2 prep bSSFP; T 2 *: 23.4 ± 2.6 ms by BB‐meGRE). Compared with conventional cine, MyoFoldstar images exhibited reduced myocardium–blood contrast, yet left ventricular function quantifications were mainly preserved ( r > 0.9). Phantom results indicated that MyoFoldstar achieves good accuracy relative to reference standards. MyoFoldstar enables rapid myocardial T 1 , T 2 , T 2 *, and cine imaging within a single breath‐hold scan, delivering a time‐saving and comprehensive assessment of cardiovascular magnetization resonance.
- 28 May 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (7) , e70320
A Mixed Single‐Echo and Multiecho MyoFoldstar for Simultaneous Quantification of Myocardial T 1 , T 2 , T 2 *, and Wall Motion
This study aimed to propose a mixed single‐echo and multiecho MyoFoldstar sequence enabling simultaneous myocardial multiparametric mapping and wall‐motion quantification. MyoFoldstar is designed as a 2D, single breath‐holding sequence that sequentially performs joint T 1 / T 2 mapping, T 2 * mapping, and cine imaging within 17 heartbeats, using a golden‐angle radial gradient‐echo (GRE) readout and ECG synchronization. The joint T 1 / T 2 mapping collects seven single‐shot, single‐echo images on the first seven heartbeats with inversion and T 2 preparation ( T 2 prep). The subsequent T 2 * mapping acquires multishot, multiecho data over six heartbeats, followed by segmented cine with a single‐echo readout over four heartbeats. In vivo feasibility was demonstrated in 12 healthy volunteers at 3 T and compared with conventional single‐task sequences (MOLLI and SASHA for T 1 , T 2 prep bSSFP for T 2 , and BB‐meGRE for T 2 *). Accuracy was validated in phantom studies. Both in vivo and phantom studies demonstrated the feasibility of MyoFoldstar for simultaneously acquiring cardiac T 1 , T 2 , T 2 *, and cine imaging. MyoFoldstar‐derived myocardial T 1 (1521 ± 102 ms), T 2 (43.2 ± 3.0 ms), and T 2 * (19.2 ± 2.4 ms) showed good agreement with values from conventional single‐task sequences ( T 1 : 1248 ± 35 ms by MOLLI and 1580 ± 38 ms by SASHA; T 2 : 43.5 ± 2.2 ms by T 2 prep bSSFP; T 2 *: 23.4 ± 2.6 ms by BB‐meGRE). Compared with conventional cine, MyoFoldstar images exhibited reduced myocardium–blood contrast, yet left ventricular function quantifications were mainly preserved ( r > 0.9). Phantom results indicated that MyoFoldstar achieves good accuracy relative to reference standards. MyoFoldstar enables rapid myocardial T 1 , T 2 , T 2 *, and cine imaging within a single breath‐hold scan, delivering a time‐saving and comprehensive assessment of cardiovascular magnetization resonance.
- Open Access
- 30 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Low-FREquency Deep TRanscranial Magnetic Stimulation in ACute Ischaemic StrokE within 48 Hours (RETRACE-I): rationale and design of a randomised, multicentre, open-label, blinded endpoint trial
Background: Acute ischaemic stroke often leads to significant disability and mortality. Secondary brain injury caused by post-stroke immune and inflammatory responses worsens outcomes. Aim: To assess the efficacy and safety of low-frequency deep transcranial magnetic stimulation (LF-dTMS), delivered with an H4 coil to target the insular and prefrontal cortex, and its potential effects on neuroimmune activity and recovery. Design: This randomised, multicentre, open-label, parallel-group trial with blinded outcome assessment evaluates early LF-dTMS at 1 Hz using the H4 coil in adults with anterior-circulation acute ischaemic stroke treated within 48 hours of onset. Participants are randomly assigned in a 1:1 ratio to receive either standard care plus LF-dTMS or standard care alone. Active LF-dTMS is delivered as two sessions per day, 1200 pulses per session, for three consecutive days. Study outcomes: The primary efficacy outcome is the growth in infarct volume from baseline to day 3, measured by diffusion-weighted MRI. The primary safety outcome is symptomatic intracranial haemorrhage within 3 days of treatment. Secondary outcomes include the modified Rankin Scale and serious adverse events at 90 days. Exploratory analyses in a predefined subgroup will involve dynamic plasma proteomics and single-cell RNA sequencing of peripheral mononuclear cells to understand immune responses (days 0, 3, 7), as well as resting-state functional MRI to evaluate the effects of neuromodulation on brain network connectivity. Summary: This study will evaluate the feasibility, safety and preliminary efficacy of early LF-dTMS in acute stroke. It will provide proof-of-concept data on whether modulating post-stroke inflammation and neuroplasticity can improve outcomes. The findings will inform the design of a large definitive trial. Trial registration number: NCT06064734 .
- 30 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessLow-FREquency Deep TRanscranial Magnetic Stimulation in ACute Ischaemic StrokE within 48 Hours (RETRACE-I): rationale and design of a randomised, multicentre, open-label, blinded endpoint trial
Background: Acute ischaemic stroke often leads to significant disability and mortality. Secondary brain injury caused by post-stroke immune and inflammatory responses worsens outcomes. Aim: To assess the efficacy and safety of low-frequency deep transcranial magnetic stimulation (LF-dTMS), delivered with an H4 coil to target the insular and prefrontal cortex, and its potential effects on neuroimmune activity and recovery. Design: This randomised, multicentre, open-label, parallel-group trial with blinded outcome assessment evaluates early LF-dTMS at 1 Hz using the H4 coil in adults with anterior-circulation acute ischaemic stroke treated within 48 hours of onset. Participants are randomly assigned in a 1:1 ratio to receive either standard care plus LF-dTMS or standard care alone. Active LF-dTMS is delivered as two sessions per day, 1200 pulses per session, for three consecutive days. Study outcomes: The primary efficacy outcome is the growth in infarct volume from baseline to day 3, measured by diffusion-weighted MRI. The primary safety outcome is symptomatic intracranial haemorrhage within 3 days of treatment. Secondary outcomes include the modified Rankin Scale and serious adverse events at 90 days. Exploratory analyses in a predefined subgroup will involve dynamic plasma proteomics and single-cell RNA sequencing of peripheral mononuclear cells to understand immune responses (days 0, 3, 7), as well as resting-state functional MRI to evaluate the effects of neuromodulation on brain network connectivity. Summary: This study will evaluate the feasibility, safety and preliminary efficacy of early LF-dTMS in acute stroke. It will provide proof-of-concept data on whether modulating post-stroke inflammation and neuroplasticity can improve outcomes. The findings will inform the design of a large definitive trial. Trial registration number: NCT06064734 .
- Open Access
- 6 October 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3) , 330-340
Association between elevated adiponectin levels and 5-year risk of clinical outcomes in patients with ischaemic stroke
Background: The role of adiponectin (ADPN) in stroke remains debatable, despite its significant impact as a major adipocytokine on cardiovascular (CV) diseases. This study aimed to assess the association between ADPN and 5-year mortality, functional outcome and recurrence in Chinese individuals with first ischaemic stroke (IS). Methods: This prospective, multicentre study recruited IS patients from 201 hospitals in China between August 2015 and March 2018. Multivariable Cox regression evaluated ADPN’s association with mortality/recurrence, while logistic regression analysed poor functional outcomes (modified Rankin Scale score 3–6 and 3–5). Results: Among 8086 patients (median age 62; 31.8% female), there were 710 deaths, 1134 recurrences and 1223 poor functional outcomes (modified Rankin Scale 3–6). Higher baseline ADPN levels were significantly associated with increased risk of 5-year non-CV mortality (adjusted HR Q4 vs Q1 =1.47 (95% CI 1.10 to 1.96), p=0.06) after adjustment for age, sex, body mass index and National Institutes of Health Stroke Scale. No independent associations were found between ADPN and CV mortality, stroke recurrence or poor functional outcome. Subgroup analysis revealed a significant association between ADPN and 5-year mortality from various causes among patients with cardioembolism (adjusted HR Q4 vs. Q1 =2.39 (95% CI 1.24 to 4.62), p=0.007) and large artery atherosclerosis (adjusted HR Q4 vs Q1 =2.16 (95% CI 1.34 to 3.47), p=0.004). Conclusions: Elevated baseline ADPN levels were independently associated with increased 5-year non-CV mortality in Chinese IS patients, especially among those with mild neurological impairment. These findings suggest ADPN may serve as a prognostic biomarker for systemic vulnerability after stroke.
- 6 October 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3) , 330-340
Open AccessAssociation between elevated adiponectin levels and 5-year risk of clinical outcomes in patients with ischaemic stroke
Background: The role of adiponectin (ADPN) in stroke remains debatable, despite its significant impact as a major adipocytokine on cardiovascular (CV) diseases. This study aimed to assess the association between ADPN and 5-year mortality, functional outcome and recurrence in Chinese individuals with first ischaemic stroke (IS). Methods: This prospective, multicentre study recruited IS patients from 201 hospitals in China between August 2015 and March 2018. Multivariable Cox regression evaluated ADPN’s association with mortality/recurrence, while logistic regression analysed poor functional outcomes (modified Rankin Scale score 3–6 and 3–5). Results: Among 8086 patients (median age 62; 31.8% female), there were 710 deaths, 1134 recurrences and 1223 poor functional outcomes (modified Rankin Scale 3–6). Higher baseline ADPN levels were significantly associated with increased risk of 5-year non-CV mortality (adjusted HR Q4 vs Q1 =1.47 (95% CI 1.10 to 1.96), p=0.06) after adjustment for age, sex, body mass index and National Institutes of Health Stroke Scale. No independent associations were found between ADPN and CV mortality, stroke recurrence or poor functional outcome. Subgroup analysis revealed a significant association between ADPN and 5-year mortality from various causes among patients with cardioembolism (adjusted HR Q4 vs. Q1 =2.39 (95% CI 1.24 to 4.62), p=0.007) and large artery atherosclerosis (adjusted HR Q4 vs Q1 =2.16 (95% CI 1.34 to 3.47), p=0.004). Conclusions: Elevated baseline ADPN levels were independently associated with increased 5-year non-CV mortality in Chinese IS patients, especially among those with mild neurological impairment. These findings suggest ADPN may serve as a prognostic biomarker for systemic vulnerability after stroke.
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e043116
Lesion Network Mapping for Atrial Fibrillation Newly Detected on ECG or Cardiac Monitoring After Stroke
Background: Atrial fibrillation detected after stroke is a distinct clinical entity that may stem from cardiogenic‐neurogenic interactions. We aimed to illuminate the lesion network mapping of atrial fibrillation newly detected on ECG or cardiac monitoring after stroke and explore the association between the central autonomic network and occurrence of atrial fibrillation. Methods: We performed voxel‐based lesion‐symptom mapping, structural disconnection connectome mapping and functional disconnection connectome mapping to locate lesions and networks for atrial fibrillation newly detected on ECG or cardiac monitoring after stroke. We also calculated the mapping score to quantify the overlap between lesions and maps and evaluated its association with atrial fibrillation using logistic regression analysis. Results: Among 4629 patients, 149 (3.22%) had atrial fibrillation newly detected on ECG or cardiac monitoring after stroke. SDC maps revealed notable disconnections in right insular cortex, amygdala and so on with the peak Z score in the right precentral gyrus ( Z score=3.27). Functional disconnection connectome maps revealed pronounced functional disconnections in bilateral precentral/postcentral gyrus, insular cortex and so on with the peak Z score in the right insular cortex ( Z score=3.41). Region of interest analysis showed that functional/structural disconnections in some sympathetic/parasympathetic regions (eg, primary motor cortex, temporal pole) were associated with the occurrence of atrial fibrillation. Conclusions: Significant structural disconnection connectome/functional disconnection connectome mapping and central autonomic network associations were observed in patients with atrial fibrillation newly detected on ECG or cardiac monitoring after stroke, supporting the crucial role of brain networks especially the central autonomic network in the pathogenesis of atrial fibrillation detected after stroke.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e043116
Open AccessLesion Network Mapping for Atrial Fibrillation Newly Detected on ECG or Cardiac Monitoring After Stroke
Background: Atrial fibrillation detected after stroke is a distinct clinical entity that may stem from cardiogenic‐neurogenic interactions. We aimed to illuminate the lesion network mapping of atrial fibrillation newly detected on ECG or cardiac monitoring after stroke and explore the association between the central autonomic network and occurrence of atrial fibrillation. Methods: We performed voxel‐based lesion‐symptom mapping, structural disconnection connectome mapping and functional disconnection connectome mapping to locate lesions and networks for atrial fibrillation newly detected on ECG or cardiac monitoring after stroke. We also calculated the mapping score to quantify the overlap between lesions and maps and evaluated its association with atrial fibrillation using logistic regression analysis. Results: Among 4629 patients, 149 (3.22%) had atrial fibrillation newly detected on ECG or cardiac monitoring after stroke. SDC maps revealed notable disconnections in right insular cortex, amygdala and so on with the peak Z score in the right precentral gyrus ( Z score=3.27). Functional disconnection connectome maps revealed pronounced functional disconnections in bilateral precentral/postcentral gyrus, insular cortex and so on with the peak Z score in the right insular cortex ( Z score=3.41). Region of interest analysis showed that functional/structural disconnections in some sympathetic/parasympathetic regions (eg, primary motor cortex, temporal pole) were associated with the occurrence of atrial fibrillation. Conclusions: Significant structural disconnection connectome/functional disconnection connectome mapping and central autonomic network associations were observed in patients with atrial fibrillation newly detected on ECG or cardiac monitoring after stroke, supporting the crucial role of brain networks especially the central autonomic network in the pathogenesis of atrial fibrillation detected after stroke.
- 11 June 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (9) , 1090-1101
Decade trends in risk factors, treatments, and prognosis of minor ischemic stroke and TIA in China
Background: Real-world data on the long-term trends in risk factors, acute antithrombotic strategies, medication adherence, and their impact on the prognosis of minor ischemic stroke (MIS) or transient ischemic attack (TIA) are limited. Methods: We analyzed cases of acute MIS (National Institutes of Health Stroke Scale score ⩽ 3) and TIA from the China National Stroke Registries (CNSRs), a series of multicenter, nationwide hospital-based registries in China. Stroke risk factors, acute antithrombotic strategies, and adherence to secondary prevention were compared between CNSR I (2007–2008) and CNSR III (2015–2018). The main outcomes were stroke recurrence, disability (modified Rankin Scale 3–5), and all-cause mortality at 3, 6, and 12 months of follow-up. Results: In total, 15,352 patients with acute MIS or TIA were included, including 7,013 patients from CNSR I and 8,339 patients from CNSR III. Over the past decade, there has been a 10-fold increase in the acute use of dual antiplatelet therapy (3.15% in CNSR I vs 31.75% in CNSR III) and a seven-fold increase in statin adherence at the 12 month follow-up (10.56% in CNSR I vs 71.15% in CNSR III). It was also observed that the adjusted cumulative incidence of stroke recurrence (15.38% [15.29%–15.47%] vs 8.29% [8.27%–8.32%]), disability rates (11.29% [11.12%–11.46%] vs 4.38% [4.32%–4.44%]), and all-cause mortality (8.17% [8.04%–8.30%] vs 1.86% [1.83%–1.89%]) at the 12-month follow-up showed a marked decline over the decade. Risk factors such as age (per 10 years), diabetes, and prior stroke were linked to a higher risk of 12-month stroke recurrence in CNSR I (CNSR I: odds ratio (OR) and 95% confidence interval (CI), 1.25 [1.17–1.33] for age per 10 years; 1.40 [1.18–1.66] for diabetes; and 1.96 [1.68–2.27] for prior stroke), and these associations remained significant after 10 years (CNSR III: OR and 95% CI, 1.15 [1.08–1.24] for age per 10 years; 1.35 [1.13–1.61] for diabetes; and 1.54 [1.29–1.84] for prior stroke). Conclusion: The past decade has witnessed significant advancements in both acute antithrombotic strategies and medication adherence, accompanied by marked reductions in stroke recurrence, disability, and mortality. These improvements highlight a positive shift toward more effective evidence-based care for patients with MIS or TIA.
- 11 June 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (9) , 1090-1101
Decade trends in risk factors, treatments, and prognosis of minor ischemic stroke and TIA in China
Background: Real-world data on the long-term trends in risk factors, acute antithrombotic strategies, medication adherence, and their impact on the prognosis of minor ischemic stroke (MIS) or transient ischemic attack (TIA) are limited. Methods: We analyzed cases of acute MIS (National Institutes of Health Stroke Scale score ⩽ 3) and TIA from the China National Stroke Registries (CNSRs), a series of multicenter, nationwide hospital-based registries in China. Stroke risk factors, acute antithrombotic strategies, and adherence to secondary prevention were compared between CNSR I (2007–2008) and CNSR III (2015–2018). The main outcomes were stroke recurrence, disability (modified Rankin Scale 3–5), and all-cause mortality at 3, 6, and 12 months of follow-up. Results: In total, 15,352 patients with acute MIS or TIA were included, including 7,013 patients from CNSR I and 8,339 patients from CNSR III. Over the past decade, there has been a 10-fold increase in the acute use of dual antiplatelet therapy (3.15% in CNSR I vs 31.75% in CNSR III) and a seven-fold increase in statin adherence at the 12 month follow-up (10.56% in CNSR I vs 71.15% in CNSR III). It was also observed that the adjusted cumulative incidence of stroke recurrence (15.38% [15.29%–15.47%] vs 8.29% [8.27%–8.32%]), disability rates (11.29% [11.12%–11.46%] vs 4.38% [4.32%–4.44%]), and all-cause mortality (8.17% [8.04%–8.30%] vs 1.86% [1.83%–1.89%]) at the 12-month follow-up showed a marked decline over the decade. Risk factors such as age (per 10 years), diabetes, and prior stroke were linked to a higher risk of 12-month stroke recurrence in CNSR I (CNSR I: odds ratio (OR) and 95% confidence interval (CI), 1.25 [1.17–1.33] for age per 10 years; 1.40 [1.18–1.66] for diabetes; and 1.96 [1.68–2.27] for prior stroke), and these associations remained significant after 10 years (CNSR III: OR and 95% CI, 1.15 [1.08–1.24] for age per 10 years; 1.35 [1.13–1.61] for diabetes; and 1.54 [1.29–1.84] for prior stroke). Conclusion: The past decade has witnessed significant advancements in both acute antithrombotic strategies and medication adherence, accompanied by marked reductions in stroke recurrence, disability, and mortality. These improvements highlight a positive shift toward more effective evidence-based care for patients with MIS or TIA.
- Open Access
- 3 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2031
High-Sensitivity C-Reactive Protein Modifies P-Wave Terminal Force in Lead V1-Associated Prognosis in Acute Ischemic Stroke or TIA Patients
Little is known about the role of high-sensitivity C-reactive protein (hsCRP) in the relationship between P-wave terminal force in lead V1 (PTFV1) and stroke prognosis. We aimed to investigate how hsCRP influences the effect of PTFV1 on ischemic stroke recurrence and mortality. In this study, patients enrolled in the Third China National Stroke Registry, which enrolled consecutive patients who had suffered an ischemic stroke or transient ischemic attack in China, were analyzed. After excluding patients with atrial fibrillation, 8271 patients with PTFV1 and hsCRP measurements were included in this analysis. Cox regression analyses were used to assess the association between PTFV1 and stroke prognosis according to different inflammation statuses stratified by an hsCRP level of 3 mg/L. A total of 216 (2.6%) patients died, and 715 (8.6%) patients experienced ischemic stroke recurrence within 1 year. In patients with hsCRP levels ≥ 3 mg/L, elevated PTFV1 was significantly associated with mortality (HR, 1.75; 95% CI, 1.05–2.92; p = 0.03), while in those with hsCRP levels < 3 mg/L, such an association did not exist. In contrast, in patients with hsCRP levels < 3 mg/L and those with hsCRP levels ≥ 3 mg/L, elevated PTFV1 remained significantly associated with ischemic stroke recurrence. The predictive role of PTFV1 towards mortality but not ischemic stroke recurrence differed in terms of hsCRP levels.
- 3 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2031
Open AccessHigh-Sensitivity C-Reactive Protein Modifies P-Wave Terminal Force in Lead V1-Associated Prognosis in Acute Ischemic Stroke or TIA Patients
Little is known about the role of high-sensitivity C-reactive protein (hsCRP) in the relationship between P-wave terminal force in lead V1 (PTFV1) and stroke prognosis. We aimed to investigate how hsCRP influences the effect of PTFV1 on ischemic stroke recurrence and mortality. In this study, patients enrolled in the Third China National Stroke Registry, which enrolled consecutive patients who had suffered an ischemic stroke or transient ischemic attack in China, were analyzed. After excluding patients with atrial fibrillation, 8271 patients with PTFV1 and hsCRP measurements were included in this analysis. Cox regression analyses were used to assess the association between PTFV1 and stroke prognosis according to different inflammation statuses stratified by an hsCRP level of 3 mg/L. A total of 216 (2.6%) patients died, and 715 (8.6%) patients experienced ischemic stroke recurrence within 1 year. In patients with hsCRP levels ≥ 3 mg/L, elevated PTFV1 was significantly associated with mortality (HR, 1.75; 95% CI, 1.05–2.92; p = 0.03), while in those with hsCRP levels < 3 mg/L, such an association did not exist. In contrast, in patients with hsCRP levels < 3 mg/L and those with hsCRP levels ≥ 3 mg/L, elevated PTFV1 remained significantly associated with ischemic stroke recurrence. The predictive role of PTFV1 towards mortality but not ischemic stroke recurrence differed in terms of hsCRP levels.
- 4 August 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (12) , 6428-6435
A score to predict the stroke recurrence of patients with embolic stroke of undetermined source
Aim We aimed to develop a score and validate it in a prospective cohort to identify the patients with ESUS at high risk for stroke recurrence. Methods We assessed the stroke recurrence in ESUS patients of the Third China National Stroke Registry. We performed multivariable logistic regression analysis to identify predictors of stroke recurrence in the derivation cohort. Based on the coefficient of each covariate of the fitted multivariable model, we generated an integer-based point scoring system. We validated the score in the validation cohort assessing its discrimination and calibration. Results 2415 patients were included: 1611 in the derivation and 804 in the validation sample. We developed a scoring system (0–15 points) by assigning 2 points for hypertension, 3 points for diabetes mellitus, 4 points for multiple stage infarction, 2 points for watershed involved infarction, 1 points for left atrial diameter index (per increasing 2.5 mm/m2) and 3 points for without statin at discharge. The rate of stroke recurrence was 5.9% per year (95% CI 4.2–7.6%) in patients with low risk(a score of 0–5), 9.4% (7.3–11.5%) in patients with intermediate risk (6–10), and 26.8% (16.5–37.1%) in patients with high risk (11–15). The AUC (area under curve of receiver operator characteristic curve) of the score in the derivation cohort and validation cohort was, respectively, 0.60 (0.55–0.65) and 0.63 (0.56–0.70). The score was well calibrated both in the derivation cohort (p = 0.36) and validation cohort (p = 0.26) with the Hosmer–Lemeshow test. Conclusion The developed score can improve risk stratification after ESUS in secondary care settings.
- 4 August 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (12) , 6428-6435
A score to predict the stroke recurrence of patients with embolic stroke of undetermined source
Aim We aimed to develop a score and validate it in a prospective cohort to identify the patients with ESUS at high risk for stroke recurrence. Methods We assessed the stroke recurrence in ESUS patients of the Third China National Stroke Registry. We performed multivariable logistic regression analysis to identify predictors of stroke recurrence in the derivation cohort. Based on the coefficient of each covariate of the fitted multivariable model, we generated an integer-based point scoring system. We validated the score in the validation cohort assessing its discrimination and calibration. Results 2415 patients were included: 1611 in the derivation and 804 in the validation sample. We developed a scoring system (0–15 points) by assigning 2 points for hypertension, 3 points for diabetes mellitus, 4 points for multiple stage infarction, 2 points for watershed involved infarction, 1 points for left atrial diameter index (per increasing 2.5 mm/m2) and 3 points for without statin at discharge. The rate of stroke recurrence was 5.9% per year (95% CI 4.2–7.6%) in patients with low risk(a score of 0–5), 9.4% (7.3–11.5%) in patients with intermediate risk (6–10), and 26.8% (16.5–37.1%) in patients with high risk (11–15). The AUC (area under curve of receiver operator characteristic curve) of the score in the derivation cohort and validation cohort was, respectively, 0.60 (0.55–0.65) and 0.63 (0.56–0.70). The score was well calibrated both in the derivation cohort (p = 0.36) and validation cohort (p = 0.26) with the Hosmer–Lemeshow test. Conclusion The developed score can improve risk stratification after ESUS in secondary care settings.
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Placed Score: A New Risk Prediction Model to Estimate the Risk of Atrial Fibrillation Detected after Stroke in East Asian Population
Objective: We intend to establish predicting models for atrial fibrillation detected after stroke (AFDAS) based on the etiology, imaging, and biological markers of the Third China National Stroke Registry (CNSR-III). Methods: From a prospectively collected hospital-based stroke registry of the CNSR-III cohort, we excluded those with a history of atrial fibrillation or diagnosed with atrial fibrillation and atrial flutter in the ECG at admission. We implemented a series of machine-learning-based data-driven pipelines to identify predictors from 517 variables covering a comprehensive range of clinical-related factors and employed a logistic regression model to develop a score-based risk prediction tool, named PLACED. Results: Among 13,266 patients, 251 patients were identified with AFDAS. The PLACED scoring system (0–15 points) was established by assigning 1 point for PTFV1(P), 1 point for interLeukin-6(L), 2-5 points for Age(A), 2 points for Cortical involved infarction(C), 1-4 points for left atrial Enlargement(E), and 2 points for left ventricular Diastolic dysfunction (D). The PLACED score demonstrated good discriminative performance with an area under the curve of receiver operator characteristic curve (AUC) of 0.83±0.07, which outperformed existing scales, such as the AS5F (AUC 0.71±0.11) and STAF (0.73±0.05). The predicted risk of AFDAS was less than 2%, 2%-10%, and greater than 10% in patients with low (0-5 points), medium (6-9 points), and high risks (10-15 points), respectively. Conclusion: The PLACED score is a practical and efficient tool for selecting patients with higher risks of AFDAS. Future work is needed to assess the generalizability of the algorithm across clinical settings.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessPlaced Score: A New Risk Prediction Model to Estimate the Risk of Atrial Fibrillation Detected after Stroke in East Asian Population
Objective: We intend to establish predicting models for atrial fibrillation detected after stroke (AFDAS) based on the etiology, imaging, and biological markers of the Third China National Stroke Registry (CNSR-III). Methods: From a prospectively collected hospital-based stroke registry of the CNSR-III cohort, we excluded those with a history of atrial fibrillation or diagnosed with atrial fibrillation and atrial flutter in the ECG at admission. We implemented a series of machine-learning-based data-driven pipelines to identify predictors from 517 variables covering a comprehensive range of clinical-related factors and employed a logistic regression model to develop a score-based risk prediction tool, named PLACED. Results: Among 13,266 patients, 251 patients were identified with AFDAS. The PLACED scoring system (0–15 points) was established by assigning 1 point for PTFV1(P), 1 point for interLeukin-6(L), 2-5 points for Age(A), 2 points for Cortical involved infarction(C), 1-4 points for left atrial Enlargement(E), and 2 points for left ventricular Diastolic dysfunction (D). The PLACED score demonstrated good discriminative performance with an area under the curve of receiver operator characteristic curve (AUC) of 0.83±0.07, which outperformed existing scales, such as the AS5F (AUC 0.71±0.11) and STAF (0.73±0.05). The predicted risk of AFDAS was less than 2%, 2%-10%, and greater than 10% in patients with low (0-5 points), medium (6-9 points), and high risks (10-15 points), respectively. Conclusion: The PLACED score is a practical and efficient tool for selecting patients with higher risks of AFDAS. Future work is needed to assess the generalizability of the algorithm across clinical settings.
- 2 July 2021
- Published by SAGE Publications in International Journal of Stroke
- Vol. 17 (5) , 526-535
Characteristics and prognosis of patients with embolic stroke of undetermined source in China
Background and purpose: We aimed to explore the frequencies, risk factors, and natural history of embolic stroke of undetermined source (ESUS) through a national prospective registry in China. Methods: Between August 2015 and March 2018, the Third China National Stroke Registry recruited consecutive patients with ischemic stroke or transient ischemic attack in China. The baseline characteristics, risks of stroke, and prognosis in patients with embolic stroke of undetermined source were described and compared with that in patients with other causative subtypes. Results: A total of 15,166 transient ischemic attack and ischemic stroke patients were enrolled in the Third China National Stroke Registry. Among 8528 ischemic stroke with standard diagnostic work-up, 2415 (28.3%) patients were diagnosed with embolic stroke of undetermined source. The mean age was 61 years and 70% of them were male. Compared to patients with cardioembolic strokes and small vessel disease, patients with embolic stroke of undetermined source had higher prevalence of nonstenosing large artery atherosclerosis (37.93% vs. 31.26%, P = 0.008 and 37.93% vs. 34.40%, P = 0.044 respectively). The cumulative probability of stroke recurrence in patients with embolic stroke of undetermined source at three months and one year was 5.59% and 8.74%. Compared with embolic stroke of undetermined source patients (0.70% and 1.99%), patients with the large artery atherosclerosis and cardioembolic strokes had higher cumulative probability of death at three months (1.94% and 3.22%) and one year (4.17% and 7.39%). Conclusions: Embolic stroke of undetermined source is a common cause of ischemic stroke in Chinese population with a higher stroke recurrence than previously reported. It was more likely to have nonstenosing large artery atherosclerosis in patients with embolic stroke of undetermined source than with cardioembolic strokes and small vessel disease.
- 2 July 2021
- Published by SAGE Publications in International Journal of Stroke
- Vol. 17 (5) , 526-535
Characteristics and prognosis of patients with embolic stroke of undetermined source in China
Background and purpose: We aimed to explore the frequencies, risk factors, and natural history of embolic stroke of undetermined source (ESUS) through a national prospective registry in China. Methods: Between August 2015 and March 2018, the Third China National Stroke Registry recruited consecutive patients with ischemic stroke or transient ischemic attack in China. The baseline characteristics, risks of stroke, and prognosis in patients with embolic stroke of undetermined source were described and compared with that in patients with other causative subtypes. Results: A total of 15,166 transient ischemic attack and ischemic stroke patients were enrolled in the Third China National Stroke Registry. Among 8528 ischemic stroke with standard diagnostic work-up, 2415 (28.3%) patients were diagnosed with embolic stroke of undetermined source. The mean age was 61 years and 70% of them were male. Compared to patients with cardioembolic strokes and small vessel disease, patients with embolic stroke of undetermined source had higher prevalence of nonstenosing large artery atherosclerosis (37.93% vs. 31.26%, P = 0.008 and 37.93% vs. 34.40%, P = 0.044 respectively). The cumulative probability of stroke recurrence in patients with embolic stroke of undetermined source at three months and one year was 5.59% and 8.74%. Compared with embolic stroke of undetermined source patients (0.70% and 1.99%), patients with the large artery atherosclerosis and cardioembolic strokes had higher cumulative probability of death at three months (1.94% and 3.22%) and one year (4.17% and 7.39%). Conclusions: Embolic stroke of undetermined source is a common cause of ischemic stroke in Chinese population with a higher stroke recurrence than previously reported. It was more likely to have nonstenosing large artery atherosclerosis in patients with embolic stroke of undetermined source than with cardioembolic strokes and small vessel disease.
- Open Access
- 4 December 2017
- Published by Springer Nature in BMC Neurology
- Vol. 17 (1) , 1-7
Atrial fibrillation is not uncommon among patients with ischemic stroke and transient ischemic stroke in China
Atrial fibrillation (AF) is reported to be a less frequent cause of ischemic stroke in China than in Europe and North America, but it is not clear whether this is due to underestimation. Our aim was to define the true frequency of AF-associated stroke, to determine the yield of 6-day Holter ECG to detect AF in Chinese stroke patients, and to elucidate predictors of newly detected AF. Patients with acute ischemic stroke or transient ischemic attack (TIA) were enrolled in a prospective, multicenter cohort study of 6-day Holter monitoring within 7 days after stroke onset at 20 sites in China between 2013 and 2015. Independent predictors of newly-detected AF were determined by multivariate analysis. Among 1511 patients with ischemic stroke and TIA (mean age 63 years, 33.1% women), 305 (20.2%) had either previously known (196, 13.0%) or AF newly-detected by electrocardiography (53, 3.5%) or by 6-day Holter monitoring (56/1262, 4.4%). A history of heart failure (OR = 4.70, 95%CI, 1.64–13.5), advanced age (OR = 1.06, 95%CI, 1.04–1.09), NIHSS at admission (OR = 1.06, 95%CI, 1.02–1.10), blood high density lipoprotein (HDL) (OR = 1.52, 95%CI, 1.09–2.13), together with blood triglycerides (OR = 0.64, 95%CI, 0.45–0.91) were independently associated with newly-detected AF. Contrary to previous reports, AF-associated stroke is frequent (20%) in China if systemically sought. Prolonged noninvasive cardiac rhythm monitoring importantly increases AF detection in patients with recent ischemic stroke and TIA in China. Advanced age, history of heart failure, and higher admission NIHSS and higher level of HDL were independent indicators of newly-detected AF. NCT02156765 (June 5, 2014).
- 4 December 2017
- Published by Springer Nature in BMC Neurology
- Vol. 17 (1) , 1-7
Open AccessAtrial fibrillation is not uncommon among patients with ischemic stroke and transient ischemic stroke in China
Atrial fibrillation (AF) is reported to be a less frequent cause of ischemic stroke in China than in Europe and North America, but it is not clear whether this is due to underestimation. Our aim was to define the true frequency of AF-associated stroke, to determine the yield of 6-day Holter ECG to detect AF in Chinese stroke patients, and to elucidate predictors of newly detected AF. Patients with acute ischemic stroke or transient ischemic attack (TIA) were enrolled in a prospective, multicenter cohort study of 6-day Holter monitoring within 7 days after stroke onset at 20 sites in China between 2013 and 2015. Independent predictors of newly-detected AF were determined by multivariate analysis. Among 1511 patients with ischemic stroke and TIA (mean age 63 years, 33.1% women), 305 (20.2%) had either previously known (196, 13.0%) or AF newly-detected by electrocardiography (53, 3.5%) or by 6-day Holter monitoring (56/1262, 4.4%). A history of heart failure (OR = 4.70, 95%CI, 1.64–13.5), advanced age (OR = 1.06, 95%CI, 1.04–1.09), NIHSS at admission (OR = 1.06, 95%CI, 1.02–1.10), blood high density lipoprotein (HDL) (OR = 1.52, 95%CI, 1.09–2.13), together with blood triglycerides (OR = 0.64, 95%CI, 0.45–0.91) were independently associated with newly-detected AF. Contrary to previous reports, AF-associated stroke is frequent (20%) in China if systemically sought. Prolonged noninvasive cardiac rhythm monitoring importantly increases AF detection in patients with recent ischemic stroke and TIA in China. Advanced age, history of heart failure, and higher admission NIHSS and higher level of HDL were independent indicators of newly-detected AF. NCT02156765 (June 5, 2014).